Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;8(1):49.
doi: 10.1038/s41541-023-00644-8.

Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy

Peter Goon #  1 , Odile Sauzet #  2 , Matthias Schuermann  3 , Felix Oppel  3 , SenYao Shao  3 , Lars-Uwe Scholtz  3 , Holger Sudhoff  3 , Martin Goerner  4
Affiliations

Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy

Peter Goon et al. NPJ Vaccines. .

Abstract

Recurrent Respiratory Papillomatosis(RRP) is a rare disease with severe morbidity. Treatment is surgical. Prevailing viewpoint is that prophylactic HPV vaccines do not have therapeutic benefit due to their modus operandi. Studies on HPV vaccination alongside surgery were meta-analysed to test effect on burden of disease. Databases were accessed Nov and Dec 2021 [PubMed, Cochrane, Embase and Web of Science]. Main outcome measured was: Mean paired differences in the number of surgeries or recurrences per month. Analyses was performed using: Random effect maximal likelihood estimation model using the Stata module Mataan(StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX:StataCorp LLC.) Our results found n = 38 patients, suitable for syntheses with one previous meta-analyses (4 published, 2 unpublished studies) n = 63, total of n = 101 patients. Analyses rendered an overall reduction of 0.123 recurrences or surgeries per month (95% confidence interval [0.064, 0.183]). Our meta-analyses concludes that HPV vaccine is a beneficial adjunct therapy alongside surgery.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE form (available on request from the corresponding author) and declare no competing interests.

Figures

Fig. 1
Fig. 1. Juvenile Recurrent Respiratory Papillomatosis.
a At Surgery (>80 surgeries in previous 4 years). b Three months Post-Surgery (1a) and HPV vaccine.
Fig. 2
Fig. 2. Flow diagram for search.
PRISMA flow diagram.
Fig. 3
Fig. 3. Analysis - Forest Plot of Random Effect Maximal Likelihood Estimation Model.
Forest plot of random effect maximal likelihood estimation.
See this image and copyright information in PMC

References

    1. Donne AJ, Hampson L, Homer JJ, Hampson IN. The role of HPV type in recurrent respiratory papillomatosis. Int J. Pediatr. Otorhinolaryngol. 2010;74:7–14. doi: 10.1016/j.ijporl.2009.09.004. - DOI - PubMed
    1. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24:S3/35–S3/341. doi: 10.1016/j.vaccine.2006.06.015. - DOI - PubMed
    1. Hoesli RC, Wingo ML, Richardson BE, Bastian RW. Identification of 11 different HPV subtypes in adult patients with recurrent respiratory papillomatosis. Otolaryngol. Head. Neck Surg. 2020;163:785–790. doi: 10.1177/0194599820931817. - DOI - PubMed
    1. Penaloza-Plascencia M, et al. Molecular identification of 7 human papillomavirus types in recurrent respiratory papillomatosis. Arch. Otolaryngol. Head. Neck Surg. 2000;126:1119–1123. doi: 10.1001/archotol.126.9.1119. - DOI - PubMed
    1. Sanchez GI, et al. Human papillomavirus genotype detection in recurrent respiratory papillomatosis (RRP) in Colombia. Head. Neck. 2013;35:229–234. doi: 10.1002/hed.22953. - DOI - PubMed